Tumor-infiltrating NKG2A+ CD8+ T cells, prominent in lung cancer, display TRM and exhausted T cell markers, suggesting a target for efficient anti-lung cancer immunotherapy [184,185]. The gene discussed is CD8A; the disease is lung cancer.